SCHEMBL4425213

SCHEMBL4425213

Cc1c(S(=O)(=O)n2c(=O)n(C3=CCNCC3)c3ccccc32)sc2ccc(Cl)cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 16/20 0.54
KDM4E B2RXH2 1/20 0.42
SLC2A1 P11166 1/20 0.40
AKR1B1 P15121 1/20 0.39
HTR1A P08908 4/20 0.38
HTR1D P28221 4/20 0.38
HTR1B P28222 4/20 0.38
HTR2C P28335 3/20 0.38
DRD2 P14416 2/20 0.38
HTR7 P34969 2/20 0.38
ADRA1B P35368 2/20 0.38
DRD3 P35462 2/20 0.38
HTR4 Q13639 2/20 0.38
DRD1 P21728 1/20 0.38
DRD4 P21917 1/20 0.38
HTR2A P28223 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP1A2 P05177 1/20 0.37
ADRB1 P08588 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4432173 0.78 HTR6 (0.59) HTR6KDM4EHTR2CDRD3HTR2A
SCHEMBL4427807 0.78 HTR6 (0.53) HTR6SLC2A1AKR1B1HTR1AHTR1D
SCHEMBL4420503 0.76 HTR6 (0.61) HTR6KDM4EHTR1AHTR2CHTR7
SCHEMBL4420871 0.76 HTR6 (0.61) HTR6KDM4EHTR1AHTR2CHTR7
SCHEMBL4417941 0.75 HTR6 (0.60) HTR6KDM4EAKR1B1HTR2CDRD3
SCHEMBL4429587 0.74 HTR6 (0.59) HTR6KDM4EHTR2CDRD3HTR2A
SCHEMBL4417992 0.73 HTR6 (0.56) HTR6KDM4EHTR2CDRD3HTR2A
SCHEMBL4419390 0.73 HTR6 (0.57) HTR6KDM4EHTR1AHTR2CHTR7
SCHEMBL4428396 0.72 HTR6 (0.61) HTR6KDM4EHTR1AHTR2CHTR7
SCHEMBL4419370 0.72 HTR6 (0.59) HTR6AKR1B1NPSR1L3MBTL1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544701-B2 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-09 US claimed
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US claimed
US-7544701-B2 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-09 US disclosed
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR1B HTR6 1/4885KDM4E 2965/4885SLC2A1 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.